Evidence map›Paper›PMID 40410386›Full record

ArticleEuropean journal of human genetics : EJHG2025

Workflow analysis and evaluation of a next-generation phenotyping tool: A qualitative study of Face2Gene.

Katharina Wenderott, Jim Krups, Fiona Zaruchas, Peter Krawitz, Matthias Weigl, Hellen Lesmann

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Uncertainty, ethics, and progress in genomic medicine.European journal of human genetics : EJHG · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katharina WenderottInstitute for Patient Safety, University Hospital Bonn, Bonn, Germany. katharina.wenderott@ukbonn.de.ORCID 0000-0002-6335-4231
Jim KrupsInstitute for Patient Safety, University Hospital Bonn, Bonn, Germany.
Fiona ZaruchasInstitute for Patient Safety, University Hospital Bonn, Bonn, Germany.
Peter KrawitzInstitute for Genomic Statistics and Bioinformatics, University of Bonn, Bonn, Germany.ORCID 0009-0008-1789-3200
Matthias Weigl *Institute for Patient Safety, University Hospital Bonn, Bonn, Germany.ORCID 0000-0003-2408-1725
Hellen Lesmann *Institute for Genomic Statistics and Bioinformatics, University of Bonn, Bonn, Germany.ORCID 0000-0001-7985-1702

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diagnosis of rare genetic disorders often involves prolonged delays, with facial features serving as key diagnostic clues. Next-Generation Phenotyping (NGP) tools, such as Face2Gene, utilize Artificial Intelligence (AI)-driven algorithms to analyze patient photographs and list differential diagnoses based on facial dysmorphism. Despite their growing use and proven clinical value, their integration into clinical workflows remains poorly understood. This study evaluates Face2Gene's implementation into routine clinical care with barriers and facilitators to successful adoption. We conducted a literature review, followed by in-depth interviews with 15 geneticists across university hospitals in Germany. Results showed an overall positive appraisal of the tool among clinicians with emphasis on its usability. Key workflow barriers comprised IT integration and patient consent process. Despite being an additional step in the diagnostic pathway, Face2Gene has been effectively incorporated into geneticists' diagnostic routines, facilitating decision processes, and potentially expediting diagnoses for some patients. Our findings contribute to the existing literature on NGP technologies by demonstrating that effective integration of Face2Gene can enhance clinicians' efficiency and quality of work. To maximize impact of NGP technologies in genetic medicine, future implementation efforts should strive for clinicians' acceptance particularly through user-friendly design and sustained organizational support in course of workflow implementation. Study registration: German Register for Clinical Trials (DRKS) DRKS00032436.

Indexed as

Genetic TestingPhenotypeRare DiseasesWorkflowArtificial IntelligenceHumans

Identifiers

PMID40410386
PMCPMC12480590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.